cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-987Research ArticleИНФАРКТ МИОКАРДАMYOCARDIAL INFARCTIONПрименение ингибиторов ангиотензин-превращающего фермента у больных острым инфарктом миокардаACE inhibitors in patients with acute myocardial infarctionТерещенкоС. Н.TereshchenkoS. N.stereschenko@yandex.ruДжаианиН. А.DzhaianiN. A.stereschenko@yandex.ruМосковский государственный медико-стоматологический университет Росздрава, МоскваMoscow State Medico-Stomatological University, Ministry of Health of the Russian Federation, Moscow200520082005445559Copyright © Терещенко С.Н., Джаиани Н.А., 20052005Терещенко С.Н., Джаиани Н.А.Tereshchenko S.N., Dzhaiani N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/987

Работа посвящена современным возможностям применения ингибиторов ангиотензин-превращающего фермента (ИАПФ) у больных острым инфарктом миокарда (ОИМ). Эффективность ИАПФ анализируется в соответствии с результатами крупных, рандомизированных исследований. Эти исследования продемонстрировали позитивное влияние препаратов в отношении сердечно-сосудистых событий, в частности ИАПФ снижали летальность, число случаев развития недостаточности кровообращения, потребность в реваскуляризации, уменьшали частоту ишемических событий, госпитализаций по поводу нестабильной стенокардии и ИМ. Особое внимание уделяется эффективности ИАПФ в зависимости от недифференцированного и избирательного подхода при отборе пациентов для включения в клинические испытания, а также в зависимости от сроков начала терапии.

The article is devoted to modern perspectives of ACE inhibitor therapy in patients with acute myocardial infarction (AMI). ACE inhibitor efficacy is analyzed, according to the results of large randomized studies. These trials have demonstrated ACE inhibitors’ positive effects on cardiovascular event rates. In particular, ACE inhibitors reduced lethality, incidence of heart failure, ischemic events, revascularization, hospitalization due to unstable angina and MI. Varying ACE inhibitors’ effectiveness in general vs individual approach to recruiting subjects into clinical trials, and in various therapy start regimens, is emphasized.

инфаркт миокардаингибиторы ангиотензин-превращающего ферментасердечнососудистые событияmyocardial infarctionACE inhibitorscardiovascular eventsReferencesКириченко А.А. Хроническая застойная сердечная недостаточность у больных после инфаркта миокарда: механизм развития и возможные методы коррекции. РМЖ. 1998; 6(14): 15-8.Кириченко А.А. Хроническая застойная сердечная недостаточность у больных после инфаркта миокарда: механизм развития и возможные методы коррекции. РМЖ. 1998; 6(14): 15-8.Yusuf S, Lonn E. Anti- ischaemic effects of ACE inhibitors: review of cerrent clinical evidence and ongoing clinical trials. Eur Heart J 1998; 19(Suppl J): J36-44.Yusuf S, Lonn E. Anti- ischaemic effects of ACE inhibitors: review of cerrent clinical evidence and ongoing clinical trials. Eur Heart J 1998; 19(Suppl J): J36-44.Bertrand ME, Van Belle E. ACE inhibition and coronary artery disease. Medicographia 2001; 23: 27-32.Bertrand ME, Van Belle E. ACE inhibition and coronary artery disease. Medicographia 2001; 23: 27-32.Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary. JACC 2004; 44: 671-719.Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary. JACC 2004; 44: 671-719.Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. BMJ 1998; 316: 838-42.Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. BMJ 1998; 316: 838-42.Pfeffer MA. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993; 18 (Suppl 1): 430-5.Pfeffer MA. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993; 18 (Suppl 1): 430-5.The Acute Infarction Ramipril Effiicacy (AIRE) Study Investigators: effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.The Acute Infarction Ramipril Effiicacy (AIRE) Study Investigators: effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.Ambrosioni E, Borghi C, Magnani B. The SMILE study: the rationale, design, organization and definition of the objectives. Survival of Myocardial Infarction Long-term Evaluation. Ann Ital Med Int 1993; 8: 230-4.Ambrosioni E, Borghi C, Magnani B. The SMILE study: the rationale, design, organization and definition of the objectives. Survival of Myocardial Infarction Long-term Evaluation. Ann Ital Med Int 1993; 8: 230-4.Ambrossioni E, Borghi C, Magnani B, SMILE Study Investigators. The effect of angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after acute anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.Ambrossioni E, Borghi C, Magnani B, SMILE Study Investigators. The effect of angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after acute anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial the SAVE Investigators. N Engl J Med 1992; 327: 669-77.Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial the SAVE Investigators. N Engl J Med 1992; 327: 669-77.TRACE Study Group. A clinical trial of angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) Study. N Engl J Med 1995; 333: 1670-6.TRACE Study Group. A clinical trial of angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) Study. N Engl J Med 1995; 333: 1670-6.Swedberg K, Held P, Kjekshus J, et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-84.Swedberg K, Held P, Kjekshus J, et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-84.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4. A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspect acute myocardial infarction. Lancet 1995; 346: 669-85.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4. A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspect acute myocardial infarction. Lancet 1995; 346: 669-85.Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarcto myocardico: GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarcto myocardico: GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-7.Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-7.SOLVD Investigators. Effect of enalapril on survival in patients with rediced left ventricular ejection fractions and congestive heart gfailure. N Engl J Med 1991; 325: 293-302.SOLVD Investigators. Effect of enalapril on survival in patients with rediced left ventricular ejection fractions and congestive heart gfailure. N Engl J Med 1991; 325: 293-302.Мареев В.Ю., Скворцов А.А. Ингибиторы АПФ у больных, перенесших инфаркт миокарда. Сердце 2002; 1(1): 38-40.Мареев В.Ю., Скворцов А.А. Ингибиторы АПФ у больных, перенесших инфаркт миокарда. Сердце 2002; 1(1): 38-40.Александрия Л.Г. Гемодинамический эффект ингибиторов АПФ у больных инфарктом миокарда и его зависимость от генотипических особенностей. Автореф канд мед наук. Москва 2000.Александрия Л.Г. Гемодинамический эффект ингибиторов АПФ у больных инфарктом миокарда и его зависимость от генотипических особенностей. Автореф канд мед наук. Москва 2000.Беленков Ю.Н., Арутюнов Г.П., Глезер М.Г. и др. Рандомизированное многоцентровое сравнительное исследование ПРЕСТИЖ (оценка эффективности периндоприла по сравнению с каптоприлом у больных острым инфарктом миокарда с левожелудочковой дисфункцией). Кардиология 2005; 5: 22-9.Беленков Ю.Н., Арутюнов Г.П., Глезер М.Г. и др. Рандомизированное многоцентровое сравнительное исследование ПРЕСТИЖ (оценка эффективности периндоприла по сравнению с каптоприлом у больных острым инфарктом миокарда с левожелудочковой дисфункцией). Кардиология 2005; 5: 22-9.Anand I, Fisher L, Chiang Y-T, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-Heft). Circulation 2003; 107: 1276-81.Anand I, Fisher L, Chiang Y-T, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-Heft). Circulation 2003; 107: 1276-81.Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. JACC 2001; 38: 1934-41.Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. JACC 2001; 38: 1934-41.The PREAMI Investigators. Perindopril and remodelling in elderly with acute myocardial infarction. Cardiovascular Drugs and Therapy 2000; 14: 671-9.The PREAMI Investigators. Perindopril and remodelling in elderly with acute myocardial infarction. Cardiovascular Drugs and Therapy 2000; 14: 671-9.

The authors declare that there are no conflicts of interest present.